Cover Image

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation

Giovanni Cenderello,1 Stefania Artioli,2 Claudio Viscoli,3 Ambra Pasa,4 Mauro Giacomini,5 Barbara Giannini,5 Chiara Dentone,6 Laura Ambra Nicolini,3 Giovanni Cassola,1 Antonio Di Biagio31Infectious Diseases Unit EO, Ospedali Galliera, Genoa, 2Infectious Diseases Unit, ASL-5 Spezzina, La Spezia, 3Inf...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cenderello G (Author), Artioli S (Author), Viscoli C (Author), Pasa A (Author), Giacomini M (Author), Giannini B (Author), Dentone C (Author), Nicolini LA (Author), Cassola G (Author), Di Biagio A (Author)
Format:	Book
Published:	Dove Medical Press, 2015-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis
by: Cenderello G, et al.
Published: (2017)

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
by: Harel Dahari, et al.
Published: (2016)

Virological Mechanisms in the Coinfection between HIV and HCV
by: Maria Carla Liberto, et al.
Published: (2015)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
by: Kayali Z, et al.
Published: (2014)

Carpal tunnel syndrome in HIV-positive patients coinfected with HCV
by: A. Mastroianni, et al.
Published: (2017)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
by: Katarzyna Lipa, et al.
Published: (2018)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
by: Katarzyna Lipa, et al.
Published: (2018)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020)

Differences in the proviral HIV DNA between HIV monoinfected and HIV/HCV coinfected individuals
by: M.S. Carrillo, et al.
Published: (2017)

Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study
by: Daniel Sepúlveda-Crespo, et al.
Published: (2024)

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection
by: Olea Jr A, et al.
Published: (2018)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
by: Mir F, et al.
Published: (2017)

Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
by: Rubén Martín-Escolano, et al.
Published: (2024)

How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy
by: Lucia Taramasso, et al.
Published: (2018)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
by: Rodolfo Sacco, et al.
Published: (2020)

Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report
by: Braira Wahid
Published: (2020)

Co-infecção por HIV/HCV em hospital universitário de Recife, Brasil Coinfección por HIV/HCV en hospital universitario de Recife, Brasil HIV/HCV coinfection at an university hospital in Recife, Brazil
by: Flávia Helena Pontes de Carvalho, et al.
Published: (2009)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
by: Hui Jun Zhou, et al.
Published: (2021)

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa
by: Sylvie Boyer, et al.
Published: (2022)

Protocol Implementation for Normothermia in Surgery Settings in Italy: Budget-Impact Analysis
by: Monzani R, et al.
Published: (2020)

An Exceptional Case of Liver-Restricted High-Grade B-Cell Lymphoma in a Patient with Clinical History of HBV and HCV Coinfections
by: Connor R. Zuraski, et al.
Published: (2019)

HCV treatment in children and young adults with HIV/HCV co-infection in Europe
by: Anna Turkova, et al.
Published: (2015)

Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
by: Restelli U, et al.
Published: (2014)

Sofosbuvir: A Potential Treatment for Ebola
by: Sandra E. Reznik, et al.
Published: (2018)

Potential Use of Sofosbuvir in the Prophylaxis for Rabies
by: Sandra E. Reznik, et al.
Published: (2020)

Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials
by: Yang YM, et al.
Published: (2017)

Budget impact analysis of anakinra in the treatment of familial Mediterranean fever in Italy
by: A Aiello, et al.
Published: (2023)

Immunological Efficacy of Tenofovir Disproxil Fumarate-Containing Regimens in Patients With HIV-HBV Coinfection: A Systematic Review and Meta-Analysis
by: Taiyi Jiang, et al.
Published: (2019)

Development of a Nanocluster-Based Platform for Determination of Sofosbuvir
by: Zahra Karimzadeh, et al.
Published: (2022)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
by: Resmi Premji MD, et al.
Published: (2015)

Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
by: Maha M Elsabaawy, et al.
Published: (2019)

Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy
by: Colombo GL, et al.
Published: (2012)

Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.
by: Caroline S de Freitas, et al.
Published: (2019)

PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study
by: Javier Milara, et al.
Published: (2015)

Leishmaniasis and AIDS coinfection
by: Adriana Hozannah, et al.
Published: (2013)

Chikungunya Rickettsial Coinfection
by: Pathum Sookaromdee, et al.
Published: (2022)

Malaria and dengue coinfection
by: Amandeep Kaur, et al.
Published: (2022)

Telemedicine and specialised consultations in prisons. The example of HCV chronic hepatitis
by: C Fernández Rodríguez, et al.
Published: (2019)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019)

Raymond Schinazi Discusses the Discovery of Early Antiretroviral Agents and Sofosbuvir
by: Michael M. Lederman, et al.
Published: (2023)